The inhibitory effect of a new scFv/tP protein as siRNA delivery system to target hWAPL in cervical carcinoma

Molecular and Cellular Biochemistry

Volumn 391, Issue 1-2, 2014, Pages 77-84

  Zhang, Huilin ^a   Mao, Yuan ^b   Zhang, Feng ^c   Ye, Chunping ^a   Tong, Hua ^a   Su, Yiping ^a   Zhu, Jin ^d  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Jiangsu Province Official Hospital   (China)

^c Nanjing Medical University   (China)

^d Huadong Medical Institute of Biotechniques   (China)

Author keywords

Cervical carcinoma; EGFR; hWAPL; scFv; siRNA delivery; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; HYBRID PROTEIN; MESSENGER RNA; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY TRUNCATED PROTAMINE PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTIGEN; CARRIER PROTEIN; DNA; NUCLEAR PROTEIN; ONCOPROTEIN; PROTAMINE; PROTEIN BINDING; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; WAPAL PROTEIN, HUMAN;

ANTIGEN BINDING; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BINDING; DRUG DELIVERY SYSTEM; EXPRESSION VECTOR; FEMALE; GENE; GENE TARGETING; GENETIC TRANSFECTION; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN WINGS APART LIKE GENE; MOLECULARLY TARGETED THERAPY; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA; CELL DEATH; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE TRANSFER; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; UTERINE CERVIX TUMOR;

ANTIGENS; CARRIER PROTEINS; CELL DEATH; CELL PROLIFERATION; DNA; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE TRANSFER TECHNIQUES; HELA CELLS; HUMANS; NUCLEAR PROTEINS; PROTAMINES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; SINGLE-CHAIN ANTIBODIES; TRANSFECTION; UTERINE CERVICAL NEOPLASMS;

EID: 84900804118     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-014-1989-3     Document Type: Article

References (19)

1. Sundström K, Eloranta S, Sparén P et al (2010) Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 19:2469-2478
2. Kuroda M, Kiyono T, Oikawa K et al (2005) The human papillomavirus E6 and E7 inducible oncogene, hWAPL, exhibits potential as a therapeutic target. Br J Cancer 92:290-293 (Pubitemid 40343143)
3. Oikawa K, Akiyoshi A, Tanaka M et al (2008) Expression of various types of alternatively spliced WAPL transcripts in human cervical epithelia. Gene 423:57-62
4. Soonthornthum T, Arias-Pulido H, Joste N et al (2011) Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol 22:2166-2178
5. Lin H, Mao Y, Zhang DW et al (2013) Selection and characterization of human anti-MAGE-A1 scFv and immunotoxin. Anticancer Agents Med Chem 13:1259-1266
6. Inoh Y, Furuno T, Hirashima N et al (2013) Synergistic effect of a biosurfactant and protamine on gene transfection efficiency. Eur J Pharm Sci 49:1-9
7. Zhang F, Wang X, Tang Q et al (2011) Preparation and characterization of human anti-EGFR scFv-protamine fusion protein. Acta Universitatis Medicinalis Nanjing (Nat Sci) 31:651-655
8. Nieder C, Pawinski A, Dalhaug A et al (2012) A review of clinical trials of cetuximab combined with radiotherapy for nonsmall cell lung cancer. Radiat Oncol 7:3
9. Steele N, Anthony A, Saunders M et al (2012) A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. Br J Cancer 106: 793-798
10. Chen R, Zhang D, Mao Y et al (2012) A human Fab-based immunoconjugate specific for the LMP1 extracellular domain inhibits nasopharyngeal carcinoma growth in vitro and in vivo. Mol Cancer Ther 11:594-603
11. Bebb G, Smith C, Rorke S et al (2011) Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother Pharmacol 67:837-845
12. Kato J, O'Donnell RT, Abuhay M et al (2012) Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma. Oncoimmunology 1:1469-1475
13. Lu D, Zhu Z (2014) Construction and production of an IgG-like tetravalent bispecific antibody, IgG-single-chain Fv fusion. Methods Mol Biol 1060:185-213
14. Chen ZN, Mi L, Xu J et al (2006) Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys 65:435-444
15. Parodi G, De Luca G, Moschi G et al (2010) Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy. J Thromb Thrombolysis 30:446-451
16. Ortner A, Wernig K, Kaisler R et al (2010) VPAC receptor mediated tumor cell targeting by protamine based nanoparticles. J Drug Target 18:457-467
17. Cao M, Deng X, Su S et al (2013) Protamine sulfate-nanodiamond hybrid nanoparticles as a vector for MiR-203 restoration in esophageal carcinoma cells. Nanoscale 5:12120-12125
18. Hao H, Zhen Y, Wang Z et al (2013) A novel therapeutic drug for colon cancer: EpCAM scFv-truncated protamine (tp)-siRNA. Cell Biol Int 37:860-864
19. Song E, Zhu P, Lee SK et al (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23:709-717 (Pubitemid 41716361)